Arbutus Biopharma Corporation (ABUS) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-23

How it makes money

Moderna pays Arbutus a share of a settlement for using its patented technology in mRNA vaccines.

Moderna will pay an aggregate $950.0 million to Arbutus and Genevant. This is a noncontingent payment, meaning it is not dependent on a specific future event. Arbutus receives 20% of this amount after legal costs are subtracted.

What protects it: the moat

Arbutus uses patents to defend its technology for delivering mRNA into human cells.

The company's lipid nanoparticle technology uses microscopic particles to protect nucleic acid molecules. This enables the mRNA to travel through the body and enter a target cell's membrane.

What growth costs

The company reduced its costs by cutting its workforce and discontinuing in-house research.

In 2024, Arbutus reduced its workforce by 40% and ceased discovery efforts. In 2025, it reduced its workforce by an additional 57% and discontinued all in-house scientific research.

What could damage it

Unfavorable legal rulings could force Arbutus to return its contingent settlement money.

If a court overturns a legal victory, Arbutus might be required to return any contingent settlement payments it received, along with interest.

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Other companies in Biotechnology